[ad_1]
Shield Therapeutics PLC (LON: STX) will sign further sub-licensing deals in the coming months for its flagship iron deficiency pill.
Carl Sterritt, CEO of Shield, explains to Proactive London their preparations and explains how the progress made in 2018 will now be a stepping stone for the company to focus on growth next year.
Shield has signed an agreement giving the Dutch pharmaceutical group Norgine the right to sell the innovative treatment in Europe, Australia and New Zealand by the end of 2018.
Source link
